Sam Ropp - 15 Aug 2023 Form 4 Insider Report for Singular Genomics Systems, Inc.

Role
Chief Commercial Officer
Signature
/s/ Dalen Meeter, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Aug 2023
Net transactions value
$0
Form type
4
Filing time
17 Aug 2023, 16:31:04 UTC
Previous filing
20 Jun 2023
Next filing
15 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OMIC Employee Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 15 Aug 2023 Common Stock 100,000 $0.5355 Direct F1
transaction OMIC Employee Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 15 Aug 2023 Common Stock 100,000 $0.5355 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares vest and become exercisable in 48 equal monthly installments measured from August 15, 2023, subject to the Reporting Person's continuous service with the Issuer.
F2 Subject to the achievement of certain performance targets by December 31, 2023, the Reporting Person may earn up to 100,000 stock options pursuant to this award. Any stock options earned will vest 25% on August 15, 2024, and the remaining option shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer.